A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Clinical trial NCT05984277 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05984277
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-24
- Primary completion
- 2029-02-28
- Enrollment
- 895
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.